Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison

被引:8
|
作者
Ward, Zoe [1 ]
Mafirakureva, Nyashadzaishe [1 ]
Stone, Jack [1 ]
Keevans, Mary [2 ]
Betts-Symonds, Graham [2 ,3 ]
Crowley, Desmond [4 ]
McHugh, Tina [5 ]
Avramovic, Gordana [6 ]
Lambert, John S. [5 ,6 ]
Vickerman, Peter [1 ]
机构
[1] Univ Bristol, Bristol, Avon, England
[2] Irish Prison Serv, Dublin, Ireland
[3] Irish Red Cross, Dublin, Ireland
[4] Irish Coll Gen Practitioners, Dublin, Ireland
[5] Mater Misericordiae Univ Hosp, Dublin, Ireland
[6] Univ Coll Dublin, Sch Med, Dublin, Ireland
基金
美国国家卫生研究院;
关键词
Ireland; People who inject drugs; Cost-effectiveness; Prison; Hepatitis C virus; Direct acting antivirals; INJECT DRUGS; PUBLIC-HEALTH; INFECTION; PEOPLE; HCV; METAANALYSIS; PREVENTION; SOFOSBUVIR; MORTALITY; IMPACT;
D O I
10.1016/j.drugpo.2021.103394
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Irish prisons, there is a high proportion of people who inject drugs (PWID; 26%) and a high prevalence of HCV (16%), making prison a high priority setting for HCV testing and treatment. We evaluate the cost-effectiveness of a mass HCV screening intervention in Mountjoy Prison, Dublin, compared to the standard-of-care of intermittent screening on committal. Methods: Primary cost data was collected from the intervention using an overall provider perspective. Standard-of-care (SOC) costs were estimated through interview. All costs were inflated to 2020 Euros. An HCV transmission and disease progression model among incarcerated and community PWID and ex-injectors was calibrated to the Dublin HCV epidemic, allowing inclusion of population-level health benefits. The model used intervention data, suggesting 419 individuals were screened, 50 HCV infections diagnosed and 32 individuals initiated treatment, to project the resulting costs and health benefits (quality adjusted life years or QALYs) over 50 years with 5% discounting. The incremental cost effectiveness ratio (ICER), cost per QALY gained, was estimated for the screening intervention compared to the standard-of-care. Probabilistic sensitivity analyses (PSA) determined the probability that the intervention was cost-effective compared to a willingness-to-pay threshold of (sic)30,000/QALY as used in Ireland. The ICER for 1- or 3-yearly mass screening in all Dublin prisons was also calculated. Results: The total direct costs of the intervention (not including treatment drug costs) was (sic)82,392, with most costs being due to staff(43%) and overhead or management costs (38%). Despite having little epidemiological impact due to the small numbers treated, over 50 years the incremental cost of the intervention was (sic)36,592 and 3.8 QALYs were gained, giving a mean ICER of (sic)9,552/QALY. The majority (84%) of PSA runs were below the willingness-to-pay threshold. Yearly mass screening had an ICER of (sic)2,729/QALY compared to SOC and gave a higher net monetary benefit ((sic)7,393,382) than screening every 3 years ((sic)6,252,816). Conclusion: Prison mass screening could be a cost-effective initiative for increasing testing and treatment of HCV in Ireland.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF PRENATAL SCREENING AND IMMUNIZATION FOR HEPATITIS-B VIRUS
    AREVALO, JA
    WASHINGTON, AE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (03): : 365 - 369
  • [42] Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands
    de Vos, Anneke S.
    Janssen, Mart P.
    Zaaijer, Hans L.
    Hogema, Boris M.
    TRANSFUSION, 2017, 57 (02) : 258 - 266
  • [43] Cost-effectiveness of testing for human immunodeficiency virus and hepatitis C virus among blood transfusion recipients
    Mathoulin-Pelissier, S
    Salmi, LR
    Fialon, P
    Salamon, R
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (02): : 132 - 136
  • [44] Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
    Najafzadeh, Mehdi
    Andersson, Karin
    Shrank, William H.
    Krumme, Alexis A.
    Matlin, Olga S.
    Brennan, Troyen
    Avorn, Jerry
    Choudhry, Niteesh K.
    ANNALS OF INTERNAL MEDICINE, 2015, 162 (06) : 407 - U136
  • [45] Chronic hepatitis C virus infection and associated liver disease among the inmates of a Spanish prison
    Murcia, Jose
    Portilla, Joaquin
    Bedia, Miguel
    Palazon, Jose M.
    Sanchez-Paya, Jose
    Saiz de la Hoya, Pablo
    Paya, Artemio
    Boix, Vicente
    Merino, Esperanza
    Reus, Sergio
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2009, 27 (04): : 206 - 212
  • [46] The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients
    Linas, Benjamin P.
    Barter, Devra M.
    Leff, Jared A.
    DiLorenzo, Madeline
    Schackman, Bruce R.
    Horsburgh, Charles R.
    Assoumou, Sabrina A.
    Salomon, Joshua A.
    Weinstein, Milton C.
    Kim, Arthur Y.
    Freedberg, Kenneth A.
    AIDS, 2014, 28 (03) : 365 - 376
  • [47] The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review
    Myran, Daniel T.
    Morton, Rachael
    Biggs, Beverly-Ann
    Veldhuijzen, Irene
    Castelli, Francesco
    Anh Tran
    Staub, Lukas P.
    Agbata, Eric
    Rahman, Prinon
    Pareek, Manish
    Noori, Teymur
    Pottie, Kevin
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (09)
  • [48] Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea
    Kim, Do Young
    Wong, Gabriel
    Lee, Janet
    Kim, Myung Hwa
    Smith, Nathaniel
    Blissett, Rob
    Kim, Hyung Joon
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 993 - 1002
  • [49] Cost-Effectiveness of Screening for Chronic Hepatitis C Infection in the United States
    Eckman, Mark H.
    Gordon, Stuart C.
    Talal, Andrew
    Schiff, Eugene R.
    Sherman, Kenneth E.
    HEPATOLOGY, 2012, 56 : 261A - 261A
  • [50] Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States
    Eckman, Mark H.
    Talal, Andrew H.
    Gordon, Stuart C.
    Schiff, Eugene
    Sherman, Kenneth E.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (10) : 1382 - 1393